Diets & Weight Loss

Neoplasm

A tumor

Question: In using the neoplasm table, what do you do when there is no code in cancer in situ? When using the neoplasm table in the ICD-9-CM, how would one code cancer in situ of the temporal lobe?

Answer: You'll never find it there. What you're probably looking for is under skin: Ca in situ of temple or similar.

 


Neoplasm Related Products and News

Update for the practicing pathologist: The International Consultation On ...

Nature.com
Prior consultations have spanned the spectrum of neoplastic and non-neoplastic urologic diseases ranging from benign prostatic hyperplasia and erectile dysfunction to prostate and bladder cancer. Bladder cancer was previously addressed in 2004 in the ...
 

Adverse Effects of Testosterone Replacement Therapy

Medscape
... testosterone/deficiency, hormone replacement therapy/adverse effects, andropause/drug effects, andropause/physiology, morbidity, mortality, cardiovascular disease, myocardial infarction, prostate-specific antigen/blood, prostate neoplasm/blood ...
 

Kaiser Ignored Kidney Cyst, Woman Claims

Courthouse News Service
However, after a variety of tests over the next month, Lassiter was told she had a kidney mass, much larger than originally seen in 2008, "suspicious for neoplasm (i.e. new and abnormal growth, such as a tumor). What had been a millimeter in size (and ...
 

OXiGENE Announces Issuance of European Patent for OXi4503 in Acute ...

MarketWatch
The patent (EP 2219451 B1) is drawn to the use of OXi4503 in treating non-solid myeloid neoplasm, including acute myeloid leukemia (AML). "We are pleased to be granted this additional patent for OXi4503 in Europe, which builds on similar patents ...
 

Dana-Farber, Brigham and Women's Develop NGS Panel for Rapid Diagnosis of ...

GenomeWeb
Key genes on the panel include NPM1, CEBPA, and FLT3 for the prognosis of acute myeloid leukemia; and DNMT3A, TET2, and ASXL1 for diagnosing MDS or myeloproliferative neoplasm in patients with abnormal blood counts of uncertain cause. The Rapid ...
 

Diaxonhit: CITHY clinical study starts for Dx15 molecular test validation

Nasdaq
The target population includes categories III (atypia of indeterminate significance or follicular lesion of indeterminate significance (AUS / FLUS)) and IV (follicular neoplasm or suspicion of follicular neoplasm (FN / SFN)) of the Bethesda ...
 

Stemline Therapeutics Reports Third Quarter 2014 Financial Results and ...

CNNMoney
During the quarter, Stemline treated its first patients and is actively enrolling in a multicenter, open-label trial of SL-401 in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed/refractory acute myeloid leukemia (AML). Target ...
 

ZME Science

Scientists finds a way to halt the spread of prostate cancer with an injection
ZME Science
 

OXiGENE Announces Issuance of European Patent

ag-IP-news Agency
SOUTH SAN FRANCISCO, Calif., - OXiGENE Inc., a biopharmaceutical company developing novel cancer therapeutics, announced in a press release that the company has been granted a patent by the European Patent Office related to its current clinical ...
 

Curis Reports Third Quarter 2014 Financial Results and Pipeline Update

Nasdaq
Based on Debio 0932's profile and our discussion with expert clinical investigators, we anticipate initiating a clinical study of Debio 0932 in patients with systemic mastocytosis, a myeloproliferative neoplasm that has a strong rationale for benefit ...